Pinealon — tripeptide pineal bioregulator (Khavinson)
In short
Synthetic tripeptide studied in models of cognitive aging for direct transcriptional modulation in brain cells.
Overview
Pinealon (Glu-Asp-Arg/EDR) is a synthetic tripeptide bioregulator developed in Russia that demonstrates unique DNA-interaction capabilities for neuroprotection and cognitive enhancement. Research suggests benefits for traumatic brain injury recovery, age-related cognitive decline, and cellular aging processes through direct gene expression modulation.
Unique tripeptide that penetrates nuclear membranes to directly interact with DNA, modulating gene expression through histone H1.3 binding and MAPK/ERK pathway activation
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Khavinson et al. (Bull Exp Biol Med 2014) - reduces apoptotic cell death by 30-50% at nanomolar concentrations.
Pinealon има отличен профил на безопасност, базиран на над 40 години руски клиничен опит с над 15 милиона пациенти. Честите странични ефекти са минимални и включват реакции на мястото на инжектиране, лек стомашно-чревен дискомфорт, главоболие и умора. Не се съобщава за сериозна системна токсичност или специфично увреждане на органи при терапевтични дози. Противопоказан е при бременност и кърмене поради ограничени данни за безопасност при тези групи. Няма документирани лекарствени взаимодействия или участие на ензима цитохром P450. Качественият произход е критичен. Правете разлика между продукти за изследователски цели и такива с фармацевтично качество. Спрете употребата при: Тежко главоболие, което продължава или се влошава. Необичайни промени в настроението или депресия. Значителни нарушения на съня, продължаващи повече от една седмица. Всякакви признаци на алергична реакция (обрив, подуване, затруднено дишане). Продължителни стомашно-чревни проблеми извън леката първоначална адаптация.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Khavinson
In vitro | nM | 24-48 hours | -30-50% neuronal apoptosis
Bull Exp Biol Med · 2014
View the studyInformation about Pinealon is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
